A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses.
Détails
ID Serval
serval:BIB_5472E8A18937
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses.
Périodique
Cell host & microbe
ISSN
1934-6069 (Electronic)
ISSN-L
1931-3128
Statut éditorial
Publié
Date de publication
14/07/2021
Peer-reviewed
Oui
Volume
29
Numéro
7
Pages
1137-1150.e6
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
While the standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered 3 weeks apart, some public health authorities are spacing these doses, raising concerns about efficacy. However, data indicate that a single dose can be up to 90% effective starting 14 days post-administration. To assess the mechanisms contributing to protection, we analyzed humoral and T cell responses three weeks after a single BNT162b2 dose. We observed weak neutralizing activity elicited in SARS-CoV-2 naive individuals but strong anti-receptor binding domain and spike antibodies with Fc-mediated effector functions and cellular CD4 <sup>+</sup> T cell responses. In previously infected individuals, a single dose boosted all humoral and T cell responses, with strong correlations between T helper and antibody immunity. Our results highlight the potential role of Fc-mediated effector functions and T cell responses in vaccine efficacy. They also provide support for spacing doses to vaccinate more individuals in conditions of vaccine scarcity.
Mots-clé
Adult, Antibodies, Neutralizing/immunology, Antibodies, Viral/chemistry, Antibodies, Viral/immunology, BNT162 Vaccine, Betacoronavirus, COVID-19/immunology, COVID-19/prevention & control, COVID-19 Vaccines/administration & dosage, COVID-19 Vaccines/immunology, Carrier Proteins, Female, Humans, Immunity, Immunoglobulin Fc Fragments, Male, Middle Aged, SARS-CoV-2/immunology, T-Lymphocytes/immunology, Vaccination, Vaccines, Synthetic/immunology, Young Adult, mRNA Vaccines, ADCC, COVID-19, SARS-CoV-2, T cell responses, coronavirus, humoral responses, mRNA vaccine, neutralization, spike glycoproteins, variants
Pubmed
Web of science
Site de l'éditeur
Open Access
Oui
Création de la notice
09/05/2023 12:59
Dernière modification de la notice
29/11/2024 13:39